ATPS-55 INFLUENCE OF MAPK AND PI3K PATHWAY MUTATIONS ON RESPONSE TO TARGETED INHIBITORS

por McNeill, Robert S., Canoutas, Demitra A., Schmid, Ralf S., Bash, Ryan E., Constance, Brian H., Azam, Salma H., Reuther, Rachel A., Johnson, Gary L., Miller, C. Ryan
Publicado en Neuro Oncol (2015)

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

por McNeill, Robert S., Stroobant, Emily E., Smithberger, Erin, Canoutas, Demitra A., Butler, Madison K., Shelton, Abigail K., Patel, Shrey D., Limas, Juanita C., Skinner, Kasey R., Bash, Ryan E., Schmid, Ralf S., Miller, C. Ryan
Publicado en PLoS One (2018)

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

por McNeill, Robert S, Canoutas, Demitra A, Stuhlmiller, Timothy J, Dhruv, Harshil D, Irvin, David M, Bash, Ryan E, Angus, Steven P, Herring, Laura E, Simon, Jeremy M, Skinner, Kasey R, Limas, Juanita C, Chen, Xin, Schmid, Ralf S, Siegel, Marni B, Van Swearingen, Amanda E D, Hadler, Michael J, Sulman, Erik P, Sarkaria, Jann N, Anders, Carey K, Graves, Lee M, Berens, Michael E, Johnson, Gary L, Miller, C Ryan
Publicado en Neuro Oncol (2017)